October 21, 2016 7:33 AM ET

Life Sciences Tools and Services

Company Overview of Cirrus Pharmaceuticals, Inc.

Company Overview

Cirrus Pharmaceuticals, Inc. operates as a contract pharmaceutical development company. It develops inhalation and nasal products, including pressurized metered dose inhalers, dry powder inhalers, nebulizer solutions and suspensions, nasal sprays, and novel delivery systems; oral dosage forms, which include liquids, powders, and capsules; parenteral products; and topical and transdermal dosage forms, such as gels, creams, ointments, lotions, pastes, and sprays. The company’s services include analytical services, preformulation, formulation development, device evaluation, stability testing, and manufacturing support. It offers its services to pharmaceutical, biotechnology, veterinary, cosmeti...

511 Davis Drive

Suite 100

Morrisville, NC 27560

United States

Founded in 1997





Key Executives for Cirrus Pharmaceuticals, Inc.

Co-Founder, Chief Executive Officer and President
Director of Accounting and Finance
Executive Vice President
Director of Business Development
Chairman of Kemwell Biopharma Pvt. Ltd and Managing Director of Kemwell Biopharma Pvt. Ltd
Compensation as of Fiscal Year 2016.

Cirrus Pharmaceuticals, Inc. Key Developments

Cirrus Pharmaceuticals, Inc. Ready to Launch Clinical Trial Manufacturing at Raleigh-Durham Site

Cirrus Pharmaceuticals announced that it is ready to launch its services for manufacturing cGMP materials for early phase clinical trials in its newly constructed flexi-suite at its Raleigh-Durham, USA, site. The typical batch size offering is up to 25L and Cirrus will be able to perform one and two-step filling as well as cold filling for suspension and solution MDIs. Other than MDIs in the inhaled dosage forms, the company will offer clients dry powder filling in capsules for Dry Powder Inhalers (DPI), and manufacture of nasal solutions, suspensions, and powders.

Andrew Hamer Joins Cirrus Pharmaceuticals as VP R&D

Cirrus Pharmaceuticals announced that Andrew Hamer has joined as VP R&D. Andrew previously worked at GlaxoSmithKline as Senior Director R&D Operations in RTP.

Cirrus Pharmaceuticals to Invest in Flexible cGMP Suite in its Facility in RTP, North Carolina

Cirrus Pharmaceuticals announced that it will be investing in a flexible cGMP suite in its facility in RTP, North Carolina. With the addition of the cGMP suite, Cirrus will be able to extend its offerings in the US from contract development to manufacturing.

Similar Private Companies By Industry

Company Name Region
10X Genomics, Inc. United States
4G Clinical, Inc. United States
AAPharmaSyn LLC United States
Abiant, Inc. United States
aBioBot, Inc. United States

Recent Private Companies Transactions

April 18, 2016

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Cirrus Pharmaceuticals, Inc., please visit www.cirruspharm.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.